Anti-UGCG monoclonal antibody

Pre-made anti-UGCG monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to UGCG/UGCG products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-IP0022-Ab-1/ GM-Tg-hg-IP0022-Ab-2Anti-Human UGCG monoclonal antibodyHuman
GM-Tg-rg-IP0022-Ab-1/ GM-Tg-rg-IP0022-Ab-2Anti-Rat UGCG monoclonal antibodyRat
GM-Tg-mg-IP0022-Ab-1/ GM-Tg-mg-IP0022-Ab-2Anti-Mouse UGCG monoclonal antibodyMouse
GM-Tg-cynog-IP0022-Ab-1/ GM-Tg-cynog-IP0022-Ab-2Anti-Cynomolgus/ Rhesus macaque UGCG monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-IP0022-Ab-1/ GM-Tg-felg-IP0022-Ab-2Anti-Feline UGCG monoclonal antibodyFeline
GM-Tg-cang-IP0022-Ab-1/ GM-Tg-cang-IP0022-Ab-2Anti-Canine UGCG monoclonal antibodyCanine
GM-Tg-bovg-IP0022-Ab-1/ GM-Tg-bovg-IP0022-Ab-2Anti-Bovine UGCG monoclonal antibodyBovine
GM-Tg-equg-IP0022-Ab-1/ GM-Tg-equg-IP0022-Ab-2Anti-Equine UGCG monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-IP0022-Ab-1/ GM-Tg-hg-IP0022-Ab-2; GM-Tg-rg-IP0022-Ab-1/ GM-Tg-rg-IP0022-Ab-2;
GM-Tg-mg-IP0022-Ab-1/ GM-Tg-mg-IP0022-Ab-2; GM-Tg-cynog-IP0022-Ab-1/ GM-Tg-cynog-IP0022-Ab-2;
GM-Tg-felg-IP0022-Ab-1/ GM-Tg-felg-IP0022-Ab-2; GM-Tg-cang-IP0022-Ab-1/ GM-Tg-cang-IP0022-Ab-2;
GM-Tg-bovg-IP0022-Ab-1/ GM-Tg-bovg-IP0022-Ab-2; GM-Tg-equg-IP0022-Ab-1/ GM-Tg-equg-IP0022-Ab-2
Products NameAnti-UGCG monoclonal antibody
Formatmab
Target NameUGCG
Protein Sub-locationIntrocelluar Protein
Category of antibodyTherapeutics Target antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-UGCG monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-IP0022-Ag-1Recombinant multi-species CEGT/ UGCG/ GCS protein
    ORF Viral VectorvGMLP003640human UGCG Lentivirus particle
    ORF Viral VectorpGMLP003640human UGCG Lentivirus plasmid
    ORF Viral VectorpGMLPm002552mouse Ugcg Lentivirus plasmid
    ORF Viral VectorvGMLPm002552mouse Ugcg Lentivirus particle


    Target information

    Target IDGM-IP0022
    Target NameUGCG
    Gene ID7357,22234,83626,707875,481666,101101006,514357,100057611
    Gene Symbol and SynonymsEpcs21,GCS,GlcT-1,GLCT1,UGCG,Ugcgl
    Uniprot AccessionQ16739,Q9R0E0
    Uniprot Entry NameCEGT_HUMAN,CEGT_RAT
    Protein Sub-locationIntrocelluar Protein
    CategoryTherapeutics Target
    DiseaseN/A
    Gene EnsemblENSG00000148154
    Target ClassificationN/A

    The target: UGCG, gene name: UGCG, also named as GCS, GLCT1. This gene encodes an enzyme that catalyzes the first glycosylation step in the biosynthesis of glycosphingolipids, which are membrane components containing lipid and sugar moieties. The product of this reaction is glucosylceramide, which is the core structure of many glycosphingolipids. [provided by RefSeq, Dec 2014].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.